Tianjin Ringpu Bio-Technology Co.,Ltd. (SHE:300119)
China
· Delayed Price · Currency is CNY 19.38
+0.21 (1.10%)
Mar 10, 2026, 3:04 PM CST
SHE:300119 Revenue
Tianjin Ringpu Bio-Technology had revenue of 836.74M CNY in the quarter ending September 30, 2025, with 1.44% growth. This brings the company's revenue in the last twelve months to 3.37B, up 0.27% year-over-year. In the year 2024, Tianjin Ringpu Bio-Technology had annual revenue of 3.07B with 13.32% growth.
Revenue (ttm)
3.37B
Revenue Growth
+0.27%
P/S Ratio
2.58
Revenue / Employee
1.16M
Employees
2,900
Market Cap
8.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.07B | 360.83M | 13.32% |
| Dec 31, 2023 | 2.71B | 624.85M | 29.98% |
| Jan 1, 2023 | 2.08B | 77.11M | 3.84% |
| Jan 1, 2022 | 2.01B | 6.73M | 0.34% |
| Dec 31, 2020 | 2.00B | 533.83M | 36.40% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 27.28B |
| PharmaBlock Sciences (Nanjing) | 1.98B |
| Hunan Er-Kang Pharmaceutical | 1.29B |
| Zhejiang Xianju Pharmaceutical | 3.59B |
| Zhejiang Garden Biopharmaceutical | 1.24B |
| Harbin Pharmaceutical Group | 15.94B |
| KPC Pharmaceuticals,Inc. | 6.58B |
| Chongqing Taiji Industry(Group) Co.,Ltd | 10.04B |